3PBIOVIAN Strengthens Its International R&D Positioning With French CIR Certification At Its Sites In Spain And Finland

Pamplona-Turku - 3PBIOVIAN, a leading CDMO in process development and manufacturing of recombinant proteins and advanced therapies, has obtained the French CIR (Crédit d’Impôt Recherche) certification at its two production and development sites: Turku (Finland) and Pamplona (Spain). The certification is valid until 2027 and strengthens the company’s position as a strategic partner for international R&D projects.

The CIR certification officially recognizes the eligibility of 3PBIOVIAN’s services for French companies’ research and development programs, enabling partners to benefit from tax incentives when collaborating with the company. This framework provides an additional competitive advantage and supports the launch of new scientific and technological projects.

The Turku site has obtained the certification for the first time, while the Pamplona site has successfully completed its recertification process, having previously held this recognition. As a result, both sites now hold a fully valid CIR certification.

This milestone reinforces 3PBIOVIAN’s ability to deliver end-to-end solutions, covering both the development and manufacturing of recombinant proteins and advanced therapies, and underlines its commitment to scientific excellence and innovation.

The achievement reflects 3PBIOVIAN’s ongoing commitment to delivering high-value services, driving technological development, and fostering international collaboration, with the mission of enhancing clients’ operational excellence and ensuring that biotechnological advances reach those who matter most: patients.

ABOUT 3PBIOVIAN

3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Their service offerings include protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors for adenovirus and adeno-associated virus for gene therapy, and cell therapy products. Additionally, they provide fill and finish services for recombinant proteins and viral vectors. The company has manufacturing facilities in Pamplona-Noa in, Spain, and Turku, Finland, efficiently supporting the diverse needs of their clients, covering everything from preclinical and clinical supply to large-scale commercial manufacturing for drug substance and drug product. www.3pbiovian.com